

Serial #: 10/033,190
Reference #: EP01-002C

Enablement

On paragraph 9 of the final Office Action, claims 1-4 and 7-14 were rejected under 35 USC 112, first paragraph, for lack of enablement. The Office Action stated that the specification is enabling for a polynucleotide comprising SEQ ID NO:1 or a polynucleotide encoding an amino acid sequence SEQ ID NO: 2. The Office Action also stated that the specification does not reasonably provide enablement for the broad scope of the claims.

Applicants submit that the rejection of claims 1-4 and 7-14 under 35 U.S.C. §112, first paragraph, has been adequately addressed in view of the remarks set forth above. The Examiner is thus respectfully requested to withdraw the rejection.

CONCLUSION

It is believed that all the objections and rejections raised by the Examiner have been addressed and that the application is in condition for allowance. The Examiner is encouraged to telephone the undersigned with any questions or comments regarding this response.

Respectfully submitted,

Date: June 29, 2005


Terri L. Sale
Reg. No. 45,066

EXELIXIS, INC.
170 Harbor Way, P.O. Box 511
South San Francisco, California 94083-0511
Telephone: (650) 837-7460
Facsimile: (650) 837-7179